We are live on ! Find out more
BSTC

BioSpecifics Technologies Corp.
BSTC

Delisted

BSTC was delisted on the 1st of December, 2020.

Back to rankings

1 hedge funds and large institutions have $204K invested in BioSpecifics Technologies Corp. in 2020 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 112 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 112

99% less funds holding

Funds holding: 113 → 1 (-112)

100% less capital invested

Capital invested by funds: $254M → $204K (-$254M)

Holders
1
Holders Change
-112
Holders Change %
-99.12%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
112
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS AM
UBS AM
Illinois
+$184K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$29.9M
2
BlackRock
BlackRock
New York
-$23.8M
3
RHJA
Rice Hall James & Associates
California
-$19.5M
4
Russell Investments Group
Russell Investments Group
United Kingdom
-$17.5M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$16.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
EAM
26
Eagle Asset Management
Florida
– -$1.9M -36,073 Closed
WCM
27
Wisconsin Capital Management
Wisconsin
– -$1.91M -36,051 Closed
Boston Partners
28
Boston Partners
Massachusetts
– -$1.86M -35,169 Closed
CIM
29
Contrarius Investment Management
Jersey
– -$1.81M -34,298 Closed
MCM
30
Matarin Capital Management
New York
– -$1.78M -33,763 Closed
Charles Schwab
31
Charles Schwab
California
– -$1.59M -30,113 Closed
N
32
Nuveen
North Carolina
– -$1.45M -27,406 Closed
Los Angeles Capital Management
33
Los Angeles Capital Management
California
– -$1.4M -26,520 Closed
MPAM
34
Monarch Partners Asset Management
Massachusetts
– -$1.36M -25,751 Closed
Goldman Sachs
35
Goldman Sachs
New York
– -$1.31M -24,884 Closed
CAM
36
ClariVest Asset Management
California
– -$1.29M -24,422 Closed
TCA
37
Transcend Capital Advisors
New Jersey
– -$1.25M -23,590 Closed
IP
38
Isthmus Partners
Wisconsin
– -$1.18M -22,310 Closed
PPA
39
Parametric Portfolio Associates
Washington
– -$1.14M -21,582 Closed
SGI
40
Summit Global Investments
Utah
– -$1.12M -21,279 Closed
Ameriprise
41
Ameriprise
Minnesota
– -$1.1M -20,795 Closed
Invesco
42
Invesco
Georgia
– -$974K -18,444 Closed
AWCI
43
Alpine Woods Capital Investors
New York
– -$968K -18,324 Closed
Citadel Advisors
44
Citadel Advisors
Florida
– -$916K -17,337 Closed
MAM
45
Martingale Asset Management
Massachusetts
– -$862K -16,306 Closed
California Public Employees Retirement System
46
California Public Employees Retirement System
California
– -$753K -14,252 Closed
Swiss National Bank
47
Swiss National Bank
Switzerland
– -$692K -13,100 Closed
Cambridge Investment Research Advisors
48
Cambridge Investment Research Advisors
Iowa
– -$670K -12,680 Closed
SO
49
STRS Ohio
Ohio
– -$544K -10,300 Closed
OSAM
50
O'Shaughnessy Asset Management
Connecticut
– -$518K -9,786 Closed
1
2
3 4 5

BSTC Hedge Fund Activity: Q4 2020 in Review

1 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in BioSpecifics Technologies Corp. (BSTC) for Q4 2020, worth a combined $204K — down 100% from $254M a quarter earlier.

Sellers outnumbered buyers: 112 funds closed out of BSTC and 1 opened new positions — a net loss of 111 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was UBS AM, opening a new position worth an estimated $184K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $29.9M sold.

  • 1 institutional investor held BioSpecifics Technologies Corp. (BSTC) as of Q4 2020, down from 113 in Q3 2020.
  • Funds reported $204K of BioSpecifics Technologies Corp. stock for Q4 2020, down 100% quarter-over-quarter.
  • 1 fund opened new BioSpecifics Technologies Corp. positions in Q4 2020 and 112 closed out, a net change of -111 holders.
  • The largest BioSpecifics Technologies Corp. buyer in Q4 2020 was UBS AM, an estimated $184K added.
  • The largest BioSpecifics Technologies Corp. seller in Q4 2020 was Renaissance Technologies, an estimated $29.9M sold.

Based on aggregated 13F filings for Q4 2020.